Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 72

Similar articles for PubMed (Select 23018643)

1.

γ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γ9δ2TCRs.

Gründer C, van Dorp S, Hol S, Drent E, Straetemans T, Heijhuurs S, Scholten K, Scheper W, Sebestyen Z, Martens A, Strong R, Kuball J.

Blood. 2012 Dec 20;120(26):5153-62. doi: 10.1182/blood-2012-05-432427. Epub 2012 Sep 27.

2.

CDR3δ -grafted γ9δ2T cells mediate effective antitumor reactivity.

Zhao H, Xi X, Cui L, He W.

Cell Mol Immunol. 2012 Mar;9(2):147-54. doi: 10.1038/cmi.2011.28. Epub 2011 Sep 12.

3.

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, Rivière I, Larson SM, Koutcher JA, Sadelain M.

Cancer Res. 2005 Oct 1;65(19):9080-8.

4.

Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.

Ochi T, Fujiwara H, Okamoto S, An J, Nagai K, Shirakata T, Mineno J, Kuzushima K, Shiku H, Yasukawa M.

Blood. 2011 Aug 11;118(6):1495-503. doi: 10.1182/blood-2011-02-337089. Epub 2011 Jun 14.

5.

TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.

Spranger S, Jeremias I, Wilde S, Leisegang M, Stärck L, Mosetter B, Uckert W, Heemskerk MH, Schendel DJ, Frankenberger B.

Blood. 2012 Apr 12;119(15):3440-9. doi: 10.1182/blood-2011-06-357939. Epub 2012 Feb 27.

6.

Antitumor effector functions of T cells are dependent on in vivo priming and restricted T-cell receptor expression.

Lüking C, Kronenberger K, Frankenberger B, Nössner E, Röcken M, Mocikat R.

Int J Cancer. 2008 May 15;122(10):2280-5. doi: 10.1002/ijc.23393.

PMID:
18224683
7.

Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.

Kang N, Zhou J, Zhang T, Wang L, Lu F, Cui Y, Cui L, He W.

Cancer Biol Ther. 2009 Aug;8(16):1540-9. Epub 2009 Aug 8.

8.

Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.

Altenschmidt U, Klundt E, Groner B.

J Immunol. 1997 Dec 1;159(11):5509-15.

PMID:
9548491
9.

Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.

Kemp RA, Ronchese F.

J Immunol. 2001 Dec 1;167(11):6497-502.

10.

CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ.

Cancer Res. 2006 Nov 15;66(22):10995-1004.

11.

Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.

Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A, Chang WC, Gonzalez S, Smith D, Forman SJ, Jensen MC.

Blood. 2005 Feb 15;105(4):1622-31. Epub 2004 Oct 26.

13.

In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI.

Mamalaki A, Gritzapis AD, Kretsovali A, Belimezi M, Papamatheakis J, Perez SA, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2003 Aug;52(8):513-22. Epub 2003 Apr 25.

PMID:
12715240
14.

A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.

Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, Hong JJ, Parkhurst MR, Feldman SA, Schrump DS, Restifo NP, Robbins PF, Rosenberg SA, Morgan RA.

J Immunol. 2011 Jan 15;186(2):685-96. doi: 10.4049/jimmunol.1001775. Epub 2010 Dec 13.

15.

Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.

Wang L, Wen W, Yuan J, Helfand B, Li Y, Shi C, Tian F, Zheng J, Wang F, Chen L, Liang L, Zhou L, Lee C, Chen Z, Guo Y, Wang H, Zhang Q, Qin W.

Clin Cancer Res. 2010 Jan 1;16(1):164-73. doi: 10.1158/1078-0432.CCR-09-1758. Epub 2009 Dec 22.

16.

[Chimeric T cell receptor N29gamma redirect T lymphocytes response specific to p185HER2 in A murine model of metastatic breast cancer].

Li SP, Urban FA, Macgregor JN, Hughes DP, McDonagh KT.

Ai Zheng. 2004 Nov;23(11 Suppl):1370-5. Chinese.

PMID:
15566639
17.

Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.

Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK.

Blood. 2002 Nov 1;100(9):3155-63. Erratum in: Blood. 2003 May 15;101(10):3808.

18.
19.

Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.

Nolan KF, Yun CO, Akamatsu Y, Murphy JC, Leung SO, Beecham EJ, Junghans RP.

Clin Cancer Res. 1999 Dec;5(12):3928-41.

20.

Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor.

Hornung RL, Longo DL, Bowersox OC, Kwak LW.

J Natl Cancer Inst. 1995 Sep 6;87(17):1289-96.

PMID:
7544833
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk